Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Phenylpyruvic acid
- DrugBank Accession Number
- DB03884
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Phenylpyruvic acid (DB03884)
- Weight
- Average: 164.158
Monoisotopic: 164.047344122 - Chemical Formula
- C9H8O3
- Synonyms
- 2-oxo-3-phenylpropanic acid
- 3-phenyl-2-oxopropanoate
- 3-phenyl-2-oxopropanoic acid
- 3-phenylpyruvic acid
- alpha-Ketohydrocinnamic acid
- keto-Phenylpyruvate
- keto-phenylpyruvic acid
- Phenylbrenztraubensäure
- Phenylpyruvate
- Phenylpyruvic acid
- α-oxo-benzenepropanoic acid
- β-phenylpyruvic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UPhenylalanine dehydrogenase Not Available Rhodococcus sp. U2-Hydroxyacid oxidase 1 Not Available Humans UIndole-3-pyruvate decarboxylase Not Available Azospirillum brasilense UPutative uncharacterized protein Not Available Chromobacterium violaceum (strain ATCC 12472 / DSM 30191 / JCM 1249 / NBRC 12614 / NCIMB 9131 / NCTC 9757) UBacilysin biosynthesis protein BacB Not Available Bacillus subtilis (strain 168) UProbable chorismate mutase Not Available Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Tyrosinemia Type 3 (TYRO3) Disease Phenylketonuria Disease Phenylalanine and Tyrosine Metabolism Metabolic Tyrosinemia Type 2 (or Richner-Hanhart Syndrome) Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Calcium phenylpyruvate 7V9Q5UU79A 51828-93-4 BKMMOJVSLBZNTK-UHFFFAOYSA-L
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyruvic acid derivatives. These are compounds containing a phenylpyruvic acid moiety, which consists of a phenyl group substituted at the second position by an pyruvic acid.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylpyruvic acid derivatives
- Direct Parent
- Phenylpyruvic acid derivatives
- Alternative Parents
- Phenylpropanoic acids / Alpha-keto acids and derivatives / Alpha-hydroxy ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- 3-phenylpropanoic-acid / Alpha-hydroxy ketone / Alpha-keto acid / Aromatic homomonocyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Hydrocarbon derivative / Keto acid / Ketone
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- 2-oxo monocarboxylic acid (CHEBI:30851)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X7CO62M413
- CAS number
- 156-06-9
- InChI Key
- BTNMPGBKDVTSJY-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H8O3/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,11,12)
- IUPAC Name
- 2-oxo-3-phenylpropanoic acid
- SMILES
- OC(=O)C(=O)CC1=CC=CC=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000205
- KEGG Compound
- C00166
- PubChem Compound
- 997
- PubChem Substance
- 46506809
- ChemSpider
- 972
- BindingDB
- 50167651
- ChEBI
- 30851
- ChEMBL
- CHEMBL1162488
- ZINC
- ZINC000000901485
- PDBe Ligand
- PPY
- Wikipedia
- Phenylpyruvic_acid
- PDB Entries
- 1bw9 / 1lco / 2q5o / 2zf4 / 3h7j / 3h7y / 3h9a / 3luy / 4dqd / 4kic … show 7 more
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Diabetic Nephropathy 1 somestatus stop reason just information to hide 4 Unknown Status Treatment Muscular Atrophy 1 somestatus stop reason just information to hide 3 Not Yet Recruiting Treatment Chronic Kidney Disease (CKD) / Sarcopenia 1 somestatus stop reason just information to hide 3 Recruiting Supportive Care Nephrotic Syndrome 1 somestatus stop reason just information to hide 2, 3 Not Yet Recruiting Treatment Hemodialysis Treatment / Kidney Functions 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral Powder Oral Tablet Oral 105.000 mg Tablet Oral 67.000 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.932 mg/mL ALOGPS logP 1.3 ALOGPS logP 1.9 Chemaxon logS -2.2 ALOGPS pKa (Strongest Acidic) 3.33 Chemaxon pKa (Strongest Basic) -9.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 54.37 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 42.71 m3·mol-1 Chemaxon Polarizability 15.79 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9766 Blood Brain Barrier + 0.9392 Caco-2 permeable + 0.6174 P-glycoprotein substrate Non-substrate 0.7968 P-glycoprotein inhibitor I Non-inhibitor 0.923 P-glycoprotein inhibitor II Non-inhibitor 0.9587 Renal organic cation transporter Non-inhibitor 0.911 CYP450 2C9 substrate Non-substrate 0.8472 CYP450 2D6 substrate Non-substrate 0.942 CYP450 3A4 substrate Non-substrate 0.8014 CYP450 1A2 substrate Non-inhibitor 0.9261 CYP450 2C9 inhibitor Non-inhibitor 0.9569 CYP450 2D6 inhibitor Non-inhibitor 0.9636 CYP450 2C19 inhibitor Non-inhibitor 0.9673 CYP450 3A4 inhibitor Non-inhibitor 0.9811 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9827 Ames test Non AMES toxic 0.8852 Carcinogenicity Non-carcinogens 0.7818 Biodegradation Ready biodegradable 0.915 Rat acute toxicity 1.7408 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9751 hERG inhibition (predictor II) Non-inhibitor 0.9729
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 139.5574411 predictedDarkChem Lite v0.1.0 [M-H]- 139.3693411 predictedDarkChem Lite v0.1.0 [M-H]- 139.4163411 predictedDarkChem Lite v0.1.0 [M-H]- 139.4280411 predictedDarkChem Lite v0.1.0 [M-H]- 130.51959 predictedDeepCCS 1.0 (2019) [M+H]+ 140.4494411 predictedDarkChem Lite v0.1.0 [M+H]+ 139.4929411 predictedDarkChem Lite v0.1.0 [M+H]+ 140.3220411 predictedDarkChem Lite v0.1.0 [M+H]+ 141.0494411 predictedDarkChem Lite v0.1.0 [M+H]+ 133.44081 predictedDeepCCS 1.0 (2019) [M+Na]+ 139.3434411 predictedDarkChem Lite v0.1.0 [M+Na]+ 139.3513411 predictedDarkChem Lite v0.1.0 [M+Na]+ 139.1411411 predictedDarkChem Lite v0.1.0 [M+Na]+ 139.5838411 predictedDarkChem Lite v0.1.0 [M+Na]+ 142.4856 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Rhodococcus sp.
- Pharmacological action
- Unknown
- General Function
- Phenylalanine dehydrogenase activity
- Specific Function
- Catalyzes the reversible, NAD-dependent deamination of L-phenylalanine to phenyl pyruvate, ammonia and NADH.
- Gene Name
- pdh
- Uniprot ID
- Q59771
- Uniprot Name
- Phenylalanine dehydrogenase
- Molecular Weight
- 36608.615 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Broad substrate specificity (S)-2-hydroxy-acid oxidase that preferentially oxidizes glycolate (PubMed:10777549, PubMed:10978532, PubMed:17669354, PubMed:18215067). The glyoxylate produced by the oxidation of glycolate can then be utilized by alanine-glyoxylate aminotransferase for the peroxisomal synthesis of glycine; this pathway appears to be an important step for the detoxification of glyoxylate which, if allowed to accumulate, may be metabolized to oxalate with formation of kidney stones (PubMed:10978532, PubMed:17669354). Can also catalyze the oxidation of glyoxylate, and long chain hydroxyacids such as 2-hydroxyhexadecanoate and 2-hydroxyoctanoate, albeit with much lower catalytic efficiency (PubMed:10777549, PubMed:17669354, PubMed:18215067). Active in vitro with the artificial electron acceptor 2,6-dichlorophenolindophenol (DCIP), but O2 is believed to be the physiological electron acceptor, leading to the production of H2O2 (PubMed:10777549, PubMed:10978532, PubMed:17669354, PubMed:18215067). Is not active on L-lactate and 2-hydroxybutanoate (PubMed:10777549)
- Specific Function
- (s)-2-hydroxy-acid oxidase activity
- Gene Name
- HAO1
- Uniprot ID
- Q9UJM8
- Uniprot Name
- 2-Hydroxyacid oxidase 1
- Molecular Weight
- 40923.945 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Azospirillum brasilense
- Pharmacological action
- Unknown
- General Function
- Thiamine pyrophosphate binding
- Specific Function
- Not Available
- Gene Name
- ipdC
- Uniprot ID
- P51852
- Uniprot Name
- Indole-3-pyruvate decarboxylase
- Molecular Weight
- 57979.97 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Chromobacterium violaceum (strain ATCC 12472 / DSM 30191 / JCM 1249 / NBRC 12614 / NCIMB 9131 / NCTC 9757)
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- Not Available
- Uniprot ID
- Q7NSZ5
- Uniprot Name
- Putative uncharacterized protein
- Molecular Weight
- 21777.22 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Bacillus subtilis (strain 168)
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Part of the bacABCDE operon responsible for the biosynthesis of bacilysin.
- Gene Name
- bacB
- Uniprot ID
- P39639
- Uniprot Name
- Bacilysin biosynthesis protein BacB
- Molecular Weight
- 26839.49 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a)
- Pharmacological action
- Unknown
- General Function
- Prephenate dehydratase activity
- Specific Function
- Not Available
- Gene Name
- pheA
- Uniprot ID
- A1A2B5
- Uniprot Name
- Probable chorismate mutase
- Molecular Weight
- 35784.095 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Proton-dependent transporter of monocarboxylates such as L-lactate and pyruvate (PubMed:11101640, PubMed:23935841, PubMed:31719150). Plays a predominant role in L-lactate efflux from highly glycolytic cells (By similarity)
- Specific Function
- Lactate
- Gene Name
- SLC16A3
- Uniprot ID
- O15427
- Uniprot Name
- Monocarboxylate transporter 4
- Molecular Weight
- 49468.9 Da
References
- Manning Fox JE, Meredith D, Halestrap AP: Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000 Dec 1;529 Pt 2:285-93. [Article]
Drug created at June 13, 2005 13:24 / Updated at September 16, 2020 21:12